Earlier this year, Evonik unveiled a restructuring project that will result in up to 2,000 layoffs. Now, the German chemicals company and contract manufacturer is announcing another round of job cuts as it retools portions of its drug ingredients and nutrition businesses.
据 fiercepharma 报道,今年早些时候,全球领先的特种化工企业赢创公布了一项将导致至多2,000人失业的重组计划。现在,值其重组旗下药物成分和营养业务之际,这家德国化工及合同制造商将宣布另一轮的裁员。
Evonik is weighing strategic options—including partnerships or divestment—for its keto and pharma amino acid production sites in Ham, France, and Wuming, China, the company said Friday. Given the “outstanding potential” of Evonik’s production sites in France and China, a closure is out of the cards, the company explained.
赢创于周五表示,公司正权衡旗下位于法国哈姆的酮酸生产基地和中国南宁武鸣区的氨基酸工厂的战略选择---包括合作及撤资。赢创解释道,在汉姆和南宁武鸣基地具有“卓越的潜力”,因此不会考虑关闭这些基地,同时承诺继续为客户供货。
At the same time, Evonik will power down keto acid manufacturing in Hanau, Germany, by the end of 2025, in a move that will affect around 260 employees.
与此同时,盈创将在2025年底停止德国哈瑙基地的酮酸生产,预计将影响约260名员工
An Evonik spokesperson confirmed over email that the latest job cuts are separate from the 2,000 unveiled earlier this year.
赢创的一名发言人通过电子邮件证实,最新的裁员与今年早些时候宣布的 2,000人裁员无关。
Keto acids are used as active pharmaceutical ingredients (APIs), while pharma amino acids and their derivatives are used in medical nutrition, cosmetics, human nutrition, drug ingredients and intermediates. The business brings in revenue of around 100 million euros ($109 million) per year, Evonik noted in a release.
酮酸是一种药物活性成分(API),而药用氨基酸及其衍生物则广泛应用于医疗营养、化妆品、人体营养、原料药和医药中间体等领域。在一份新闻稿中,赢创指出,该业务每年带来约 1 亿欧元(1.09 亿美元)的收入。
Evonik’s keto and pharma amino acid rework forms part of a broader plan for the company to evolve into a “system solutions provider” focused on areas such as complex and highly potent APIs, injectable drug delivery, cell culture ingredients and “biosolutions” like lipids for mRNA and gene delivery, the company said.
赢创表示,重组酮酸和药用氨基酸,是公司发展成为“系统化解决方案提供商”的更为广泛计划的一部分,该计划专注于复杂且高效的药物活性成分(API)、可注射药物输送、细胞培养成分和“生物解决方案”等领域,如用于 mRNA 和基因递送的脂质。
“I am confident our new chapter will focus our Health Care business, and empower our customers to pioneer innovation,” Thomas Wessel, Evonik’s chief human resources officer and labor relations director, said in a statement.
在一份声明中,赢创首席人力资源官兼劳工关系总监托马斯·韦瑟尔表示,“我相信,这一转型将使医药健康业务更为集中,助力客户引领创新。”
Back in March, Evonik embarked on a multiyear reorganization program dubbed “Evonik Tailor Made,” which the company expects to cut costs by about 400 million euros annually by 2026. The strategy is expected to result in up to 2,000 layoffs—many in Germany—that will largely affect management, Evonik said at the time.
今年3月,赢创启动了一项名为“赢创定制”的多年重组计划,该公司预计到 2026年每年将削减约4亿欧元的成本。赢创曾表示,该战略预计将导致多达 2,000人被裁员,其中许多在德国,会对管理层产生很的大影响。
For all of 2023, Evonik’s sales fell 17% to 15.2 billion euros, a result the company’s CEO, Christian Kullmann, blamed on “massive, consequential changes of our economic environment.”
2023 年全年,赢创的销售额为152 亿欧元,下降17%。赢创董事会主席兼CEO库乐满将原因归结于“经济环境的巨大变化所引发”。